Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2019
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Treatment options for IBS are limited, and only a few drugs have secured FDA approval specifically for IBS-D. Current treatments include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals’ Lotronex), and two recently approved agents: an antibiotic (Salix Pharmaceuticals’ Xifaxan) and an opioid delta receptor antagonist (Allergan’s Viberzi).
QUESTIONS ANSWERED
What patient share do key therapies and brands garner by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?
How have Xifaxan and Viberzi been integrated into the treatment algorithm?
What proportion of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
What percentage of IBS-D patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
What are the product-level compliance and persistency rates among drug-treated patients with IBS-D?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.